Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease

Blarcamesine, an oral Alzheimer’s treatment, demonstrated efficacy in slowing clinical decline in early Alzheimer's patients, with a favorable safety profile. The European Medicines Agency accepted Anavex Life Sciences' Marketing Authorization Application for review.